Blocking the inflammasome: A novel approach to treat uveitis
• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Shome, Avik [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
19 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Triazolopyridazine LRRK2 kinase inhibitors - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2021 ; number:12 ; pages:2839-2857 ; extent:19 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drudis.2021.06.017 |
|---|
| Katalog-ID: |
ELV056056583 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056056583 | ||
| 003 | DE-627 | ||
| 005 | 20230624225313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2021.06.017 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica |
| 035 | |a (DE-627)ELV056056583 | ||
| 035 | |a (ELSEVIER)S1359-6446(21)00306-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |q VZ |
| 084 | |a 22 |2 ssgn | ||
| 084 | |a 46.00 |2 bkl | ||
| 100 | 1 | |a Shome, Avik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blocking the inflammasome: A novel approach to treat uveitis |
| 264 | 1 | |c 2021 | |
| 300 | |a 19 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. | ||
| 650 | 7 | |a Uveitis |2 Elsevier | |
| 650 | 7 | |a Inflammasome |2 Elsevier | |
| 650 | 7 | |a Inflammation |2 Elsevier | |
| 650 | 7 | |a Experimental autoimmune uveitis |2 Elsevier | |
| 700 | 1 | |a Mugisho, Odunayo O. |4 oth | |
| 700 | 1 | |a Niederer, Rachael L. |4 oth | |
| 700 | 1 | |a Rupenthal, Ilva D. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Triazolopyridazine LRRK2 kinase inhibitors |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011759550 |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:12 |g pages:2839-2857 |g extent:19 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drudis.2021.06.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 46.00 |j Tiermedizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 12 |h 2839-2857 |g 19 | ||
| author_variant |
a s as |
|---|---|
| matchkey_str |
shomeavikmugishoodunayooniedererrachaell:2021----:lcighifamsmaoeapoc |
| hierarchy_sort_str |
2021 |
| bklnumber |
46.00 |
| publishDate |
2021 |
| allfields |
10.1016/j.drudis.2021.06.017 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica (DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Shome, Avik verfasserin aut Blocking the inflammasome: A novel approach to treat uveitis 2021 19 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier Mugisho, Odunayo O. oth Niederer, Rachael L. oth Rupenthal, Ilva D. oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:26 year:2021 number:12 pages:2839-2857 extent:19 https://doi.org/10.1016/j.drudis.2021.06.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 26 2021 12 2839-2857 19 |
| spelling |
10.1016/j.drudis.2021.06.017 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica (DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Shome, Avik verfasserin aut Blocking the inflammasome: A novel approach to treat uveitis 2021 19 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier Mugisho, Odunayo O. oth Niederer, Rachael L. oth Rupenthal, Ilva D. oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:26 year:2021 number:12 pages:2839-2857 extent:19 https://doi.org/10.1016/j.drudis.2021.06.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 26 2021 12 2839-2857 19 |
| allfields_unstemmed |
10.1016/j.drudis.2021.06.017 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica (DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Shome, Avik verfasserin aut Blocking the inflammasome: A novel approach to treat uveitis 2021 19 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier Mugisho, Odunayo O. oth Niederer, Rachael L. oth Rupenthal, Ilva D. oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:26 year:2021 number:12 pages:2839-2857 extent:19 https://doi.org/10.1016/j.drudis.2021.06.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 26 2021 12 2839-2857 19 |
| allfieldsGer |
10.1016/j.drudis.2021.06.017 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica (DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Shome, Avik verfasserin aut Blocking the inflammasome: A novel approach to treat uveitis 2021 19 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier Mugisho, Odunayo O. oth Niederer, Rachael L. oth Rupenthal, Ilva D. oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:26 year:2021 number:12 pages:2839-2857 extent:19 https://doi.org/10.1016/j.drudis.2021.06.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 26 2021 12 2839-2857 19 |
| allfieldsSound |
10.1016/j.drudis.2021.06.017 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica (DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Shome, Avik verfasserin aut Blocking the inflammasome: A novel approach to treat uveitis 2021 19 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier Mugisho, Odunayo O. oth Niederer, Rachael L. oth Rupenthal, Ilva D. oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:26 year:2021 number:12 pages:2839-2857 extent:19 https://doi.org/10.1016/j.drudis.2021.06.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 26 2021 12 2839-2857 19 |
| language |
English |
| source |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:26 year:2021 number:12 pages:2839-2857 extent:19 |
| sourceStr |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:26 year:2021 number:12 pages:2839-2857 extent:19 |
| format_phy_str_mv |
Article |
| bklname |
Tiermedizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Uveitis Inflammasome Inflammation Experimental autoimmune uveitis |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| authorswithroles_txt_mv |
Shome, Avik @@aut@@ Mugisho, Odunayo O. @@oth@@ Niederer, Rachael L. @@oth@@ Rupenthal, Ilva D. @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011759550 |
| dewey-sort |
3540 |
| id |
ELV056056583 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056056583</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225313.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2021.06.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056056583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(21)00306-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shome, Avik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Blocking the inflammasome: A novel approach to treat uveitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">19</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uveitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammasome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Experimental autoimmune uveitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mugisho, Odunayo O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niederer, Rachael L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rupenthal, Ilva D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:2839-2857</subfield><subfield code="g">extent:19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2021.06.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2021</subfield><subfield code="e">12</subfield><subfield code="h">2839-2857</subfield><subfield code="g">19</subfield></datafield></record></collection>
|
| author |
Shome, Avik |
| spellingShingle |
Shome, Avik ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Blocking the inflammasome: A novel approach to treat uveitis |
| authorStr |
Shome, Avik |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011759550 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 610 - Medicine & health 630 - Agriculture & related technologies |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Blocking the inflammasome: A novel approach to treat uveitis Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis Elsevier |
| topic |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis |
| topic_unstemmed |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis |
| topic_browse |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Uveitis Elsevier Inflammasome Elsevier Inflammation Elsevier Experimental autoimmune uveitis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
o o m oo oom r l n rl rln i d r id idr |
| hierarchy_parent_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| hierarchy_parent_id |
ELV011759550 |
| dewey-tens |
540 - Chemistry 610 - Medicine & health 630 - Agriculture |
| hierarchy_top_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011759550 |
| title |
Blocking the inflammasome: A novel approach to treat uveitis |
| ctrlnum |
(DE-627)ELV056056583 (ELSEVIER)S1359-6446(21)00306-8 |
| title_full |
Blocking the inflammasome: A novel approach to treat uveitis |
| author_sort |
Shome, Avik |
| journal |
Triazolopyridazine LRRK2 kinase inhibitors |
| journalStr |
Triazolopyridazine LRRK2 kinase inhibitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
2839 |
| author_browse |
Shome, Avik |
| container_volume |
26 |
| physical |
19 |
| class |
540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Shome, Avik |
| doi_str_mv |
10.1016/j.drudis.2021.06.017 |
| dewey-full |
540 610 630 |
| title_sort |
blocking the inflammasome: a novel approach to treat uveitis |
| title_auth |
Blocking the inflammasome: A novel approach to treat uveitis |
| abstract |
• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. |
| abstractGer |
• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. |
| abstract_unstemmed |
• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
12 |
| title_short |
Blocking the inflammasome: A novel approach to treat uveitis |
| url |
https://doi.org/10.1016/j.drudis.2021.06.017 |
| remote_bool |
true |
| author2 |
Mugisho, Odunayo O. Niederer, Rachael L. Rupenthal, Ilva D. |
| author2Str |
Mugisho, Odunayo O. Niederer, Rachael L. Rupenthal, Ilva D. |
| ppnlink |
ELV011759550 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.drudis.2021.06.017 |
| up_date |
2024-07-06T19:18:39.298Z |
| _version_ |
1803858497293516800 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056056583</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225313.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2021.06.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001641.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056056583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(21)00306-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shome, Avik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Blocking the inflammasome: A novel approach to treat uveitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">19</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Limitations of current uveitis therapies highlight the need for targeting upstream mechanisms. • Inflammasomes play an integral part of the innate immune system in uveitis. • Inflammasomes in non-immune cells may be activated during the onset of uveitis. • Inflammasome blockers may offer a novel treatment for non-infectious uveitis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Uveitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammasome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Experimental autoimmune uveitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mugisho, Odunayo O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niederer, Rachael L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rupenthal, Ilva D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:2839-2857</subfield><subfield code="g">extent:19</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2021.06.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2021</subfield><subfield code="e">12</subfield><subfield code="h">2839-2857</subfield><subfield code="g">19</subfield></datafield></record></collection>
|
| score |
7.4000053 |